Loading
Emactuzumab is an experimental monoclonal antibody from SynOx Therapeutics in phase 3 trials for tenosynovial giant cell tumour, aimed at CSF1R.
Emactuzumab is a monoclonal antibody developed by SynOx Therapeutics and Hoffmann-La Roche. Its target is CSF1R (the sponsor names CSF-1R). The sponsor states: Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling. ClinicalTrials.gov describes the intervention as: Emactuzumab administered once every 2 weeks (q2w). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05417789 (Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT)) and NCT03768063 (A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study), in tenosynovial giant cell tumour. The largest, NCT03768063, plans to enrol 1000 participants with primary completion expected 2028-07-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling. Connects to CSF1R.
1.Emactuzumab binds CSF1R.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Emactuzumab" OR ABSTRACT:"Emactuzumab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Emactuzumab, not a curated reading list.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares CSF1R and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.